Prostate Cancer-Specific of DD3-driven oncolytic virus-harboring mK5 gene

AbstractProstate cancer (PCa) is the second most diagnosed cancer in Western male population. In this study, we insert mK5 (the mutational kringle5 of human plasminogen) into a DD3-promoted (differential display code 3) oncolytic adenovirus to construct OncoAd.mK5.DD3. E1A.dE1B, briefly, OAd.DD3.mK5. DD3 is one of the most prostate cancer specific promoters which can transcriptionally control adenoviral replication. mK5 has been proved to be able to inhibit the tumor angiogenesis and inhibit cell proliferation. Our results suggested that targeting PCa with OAd.DD3.mK5 elicited strong antitumor effect.

Download Full-text

Prostate Cancer-Specific and Potent Antitumor Effect of a DD3-Controlled Oncolytic Virus Harboring the PTEN Gene

PLoS ONE ◽

10.1371/journal.pone.0035153 ◽

2012 ◽

Vol 7 (4) ◽

pp. e35153 ◽

Cited By ~ 13

Author(s):

Miao Ding ◽

Xin Cao ◽

Hai-neng Xu ◽

Jun-kai Fan ◽

Hong-ling Huang ◽

...

Keyword(s):

Prostate Cancer ◽

Oncolytic Virus ◽

Antitumor Effect ◽

Pten Gene

Download Full-text

The role of NFATc1 in prostate cancer progression: Cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion

The Prostate ◽

10.1002/pros.22937 ◽

2015 ◽

Vol 75 (6) ◽

pp. 573-584 ◽

Cited By ~ 22

Author(s):

Takashi Kawahara ◽

Eiji Kashiwagi ◽

Hiroki Ide ◽

Yi Li ◽

Yichun Zheng ◽

...

Keyword(s):

Prostate Cancer ◽

Cell Proliferation ◽

Cancer Progression ◽

Cyclosporine A ◽

Migration And Invasion ◽

Prostate Cancer Progression ◽

Inhibit Cell Proliferation

Download Full-text

Anti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell–Based Vaccine in Prostate Cancer–Bearing Mice

International Surgery ◽

10.9738/intsurg-d-14-00147.1 ◽

2015 ◽

Vol 100 (1) ◽

pp. 155-163 ◽

Cited By ~ 11

Author(s):

Si-Ming Wei ◽

Jin-Xuan Fei ◽

Feng Tao ◽

Hang-Li Pan ◽

Qing Shen ◽

...

Keyword(s):

Prostate Cancer ◽

Monoclonal Antibody ◽

Cell Proliferation ◽

Dendritic Cells ◽

Dendritic Cell ◽

Immune Responses ◽

Antitumor Effect ◽

T Cell Proliferation ◽

Tumor Lysate ◽

Dendritic Cell Based Vaccine

Abstract In the current study, we investigated whether anti-CD27 monoclonal antibody can enhance the antitumor efficacy of a dendritic cell–based vaccine in prostate cancer–bearing mice. The overall therapeutic effect of a dendritic cell–based vaccine for prostate cancer remains moderate. A prostate cancer model was established by subcutaneous injection of RM-1 tumor cells into male C57BL/6 mice on day 0. After 4 days, tumor-bearing mice were treated with RM-1 tumor lysate–pulsed dendritic cells (i.e., dendritic cell–based vaccine), anti-CD27 monoclonal antibody, or a combination of RM-1 tumor lysate–pulsed dendritic cells with anti-CD27 monoclonal antibody. Mice were killed at 21 days after tumor cell implantation. Tumor size was measured for assessment of antitumor effect. Spleens were collected for analysis of antitumor immune responses. The antitumor immune responses were evaluated by measuring the proliferation and activity of T cells, which have the ability to kill tumor cells. The combination therapy with RM-1 tumor lysate–pulsed dendritic cells and anti-CD27 antibody significantly enhanced T-cell proliferation and activity, and significantly reduced tumor growth, compared with monotherapy with RM-1 tumor lysate–pulsed dendritic cells or anti-CD27 antibody. Our results suggest that combined treatment can strengthen antitumor efficacy by improving T-cell proliferation and activity.

Download Full-text